Literature DB >> 10436775

Pathology of incipient pancreatic cancer.

R H Hruban1, R E Wilentz, M Goggins, G J Offerhaus, C J Yeo, S E Kern.   

Abstract

BACKGROUND: An understanding of incipient pancreatic neoplasia is an essential foundation for the future development of effective screening tests for pancreatic cancer. Only when we understand early pancreatic neoplasms will we be able to detect tumors that are curable with surgical resection.
METHOD: Two approaches have helped define incipient pancreatic neoplasia. First, the histologic examination of pancreata has helped identify the most common histologic lesions in pancreatic tissues adjacent to infiltrating carcinomas. The assumption is that some of these lesions represent the precursors to the infiltrating cancers. Second, advances in molecular genetics now make it possible to define the genetic alterations present in small lesions. The demonstration that a suspected precursor lesion and an infiltrating pancreatic carcinoma share the same genetic alterations would help establish that the lesion is indeed a precursor to infiltrating pancreatic carcinoma.
RESULTS: A spectrum of intraductal proliferations in the pancreas has been found associated with infiltrating adenocarcinoma of the pancreas. These lesions, called "duct lesions," have even been identified in pancreata years before patients develop infiltrating carcinoma. Molecular genetic analysis of these lesions has revealed that they frequently harbor many of the same alterations present in infiltrating carcinoma of the pancreas. These alterations include activation of K-ras and inactivation of p16, p53 and, rarely BRCA2.
CONCLUSIONS: From these morphologic and molecular observations, we can now develop a progression model for the development of infiltrating carcinoma of the pancreas. Infiltrating carcinomas of the pancreas may arise from pancreatic duct lesions, and the progression of duct lesions to infiltrating cancer is associated with the accumulation of generalized and specific genetic alterations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10436775

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  18 in total

Review 1.  Genetic progression in the pancreatic ducts.

Authors:  R H Hruban; R E Wilentz; S E Kern
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

Review 2.  Molecular signatures of pancreatic cancer.

Authors:  Seung-Mo Hong; Jason Y Park; Ralph H Hruban; Michael Goggins
Journal:  Arch Pathol Lab Med       Date:  2011-06       Impact factor: 5.534

3.  Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia.

Authors:  N Tjarda van Heek; Alan K Meeker; Scott E Kern; Charles J Yeo; Keith D Lillemoe; John L Cameron; G Johan A Offerhaus; Jessica L Hicks; Robb E Wilentz; Michael G Goggins; Angelo M De Marzo; Ralph H Hruban; Anirban Maitra
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

4.  Clinical significance of K-ras and c-erbB-2 mutations in pancreatic adenocarcinoma and chronic pancreatitis.

Authors:  Renata Talar-Wojnarowska; Anita Gasiorowska; Beata Smolarz; Hanna Romanowicz-Makowska; Janusz Strzelczyk; Adam Janiak; Andrzej Kulig; Ewa Malecka-Panas
Journal:  Int J Gastrointest Cancer       Date:  2005

5.  Genetic progression and divergence in pancreatic carcinoma.

Authors:  M Yamano; H Fujii; T Takagaki; N Kadowaki; H Watanabe; T Shirai
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

6.  BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications.

Authors:  M Goggins; R H Hruban; S E Kern
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

7.  Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: A newly described and characterized entity.

Authors:  R E Wilentz; M Goggins; M Redston; V A Marcus; N V Adsay; T A Sohn; S S Kadkol; C J Yeo; M Choti; M Zahurak; K Johnson; M Tascilar; G J Offerhaus; R H Hruban; S E Kern
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

8.  Matrix metalloproteinase-7 is expressed by pancreatic cancer precursors and regulates acinar-to-ductal metaplasia in exocrine pancreas.

Authors:  Howard C Crawford; Charles R Scoggins; M Kay Washington; Lynn M Matrisian; Steven D Leach
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

9.  Comparison of the novel quantitative ARMS assay and an enriched PCR-ASO assay for K-ras mutations with conventional cytology on endobiliary brush cytology from 312 consecutive extrahepatic biliary stenoses.

Authors:  N T van Heek; S J Clayton; P D J Sturm; J Walker; D J Gouma; L A Noorduyn; G J A Offerhaus; J C Fox
Journal:  J Clin Pathol       Date:  2005-12       Impact factor: 3.411

Review 10.  Protein kinase D signaling in cancer: A friend or foe?

Authors:  Adhiraj Roy; Jing Ye; Fan Deng; Qiming Jane Wang
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-05-31       Impact factor: 10.680

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.